Member login

Forgot Password?

By using the members area you have already agreed to share your personal information with the BGMA/BBA so that you can access the members materials. We will store your details only as long as you are a member. Your personal information will not be shared any affiliated companies or third parties. For more information about our Privacy Policy, click here.

Return to login
Back to News index

Director General of the British Generic Manufacturers Association (BGMA) and British Biosimilars Association (BBA) Warwick Smith’s reaction to NHS Improvements study on the savings delivered from 10 medicines which have switched to generics or biosimilars

Warwick Smith Director General of the British Generic Manufacturers Association and British Biosimilars Association, said: “We welcome the study from NHS Improvement which demonstrates the significant value and increased patient access both generic and biosimilar medicines deliver. Generic medicines have for a long time saved the NHS billions of pounds on an annual basis. We now see the huge value that biosimilars can also deliver to the NHS in terms of savings and increased access to patients with chronic and often long-term diseases.”

To view the full press release please visit

https://improvement.nhs.uk/news-alerts/nhs-saves-324-million-year-switching-better-value-medicines/